A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression

Affiliations

01 May 2017

-

doi: 10.1111/bdi.12496


Abstract

Objectives: The objectives of the study were to determine if adjunctive minocycline mitigates depressive symptom severity and improves cognitive function in individuals with bipolar I/II disorder (BD). The study also aimed to determine if changes in depressive and/or cognitive symptoms over the course of treatment were associated with changes in circulating inflammatory cytokine levels.

Methods: A total of 29 (intention-to-treat: n=27) adults meeting DSM-IV-TR criteria for a major depressive episode as part of bipolar I or II disorder (i.e. Hamilton Depression Rating Scale 17-item [HAMD-17] ≥20) were enrolled in an 8-week, open-label study with adjunctive minocycline (100 mg bid). The primary outcome measure was the Montgomery-Åsberg Depression Rating Scale (MADRS). The HAMD-17, Clinical Global Impression-Severity (CGI-S), cognitive test composite scores and plasma cytokines were secondary outcome measures. Plasma cytokines were measured with the 30 V-Plex Immunoassay from Meso Scale Discovery.

Results: Adjunctive minocycline was associated with a reduction in depressive symptom severity from baseline to week 8 on the MADRS (P<.001, d=0.835), HAMD-17 (P<.001, d=0.949) and CGI-S (P<.001, d=1.09). Improvement in psychomotor speed, but not verbal memory or executive function, was observed only amongst individuals exhibiting a reduction in depression severity (P=.007, d=0.826). Levels of interleukin (IL)-12/23p40 (P=.002) were increased, while levels of IL-12p70 (P=.001) and C-C motif chemokine ligand 26 (CCL26) (P<.001) were reduced from baseline to week 8. A reduction in CCL26 levels was associated with a less favourable treatment response (P<.001).

Conclusions: Results from the pilot study suggest that adjunctive minocycline may exert antidepressant effects in individuals with bipolar depression, possibly by targeting inflammatory cytokines.

Keywords: bipolar disorder; clinical trial; cytokines; depression; inflammation; microglia; minocycline.


Similar articles

Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial.

Husain MI, Chaudhry IB, Khoso AB, Husain MO, Hodsoll J, Ansari MA, Naqvi HA, Minhas FA, Carvalho AF, Meyer JH, Deakin B, Mulsant BH, Husain N, Young AH.Lancet Psychiatry. 2020 Jun;7(6):515-527. doi: 10.1016/S2215-0366(20)30138-3. Epub 2020 May 20.PMID: 32445690 Clinical Trial.

Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial.

Dean OM, Kanchanatawan B, Ashton M, Mohebbi M, Ng CH, Maes M, Berk L, Sughondhabirom A, Tangwongchai S, Singh AB, McKenzie H, Smith DJ, Malhi GS, Dowling N, Berk M.Aust N Z J Psychiatry. 2017 Aug;51(8):829-840. doi: 10.1177/0004867417709357. Epub 2017 Jun 3.PMID: 28578592 Clinical Trial.

Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial.

Savitz JB, Teague TK, Misaki M, Macaluso M, Wurfel BE, Meyer M, Drevets D, Yates W, Gleason O, Drevets WC, Preskorn SH.Transl Psychiatry. 2018 Jan 24;8(1):27. doi: 10.1038/s41398-017-0073-7.PMID: 29362444 Free PMC article. Clinical Trial.

ECNP consensus meeting. Bipolar depression. Nice, March 2007.

Goodwin GM, Anderson I, Arango C, Bowden CL, Henry C, Mitchell PB, Nolen WA, Vieta E, Wittchen HU.Eur Neuropsychopharmacol. 2008 Jul;18(7):535-49. doi: 10.1016/j.euroneuro.2008.03.003. Epub 2008 May 23.PMID: 18501566 Review.

Novel Augmentation Strategies in Major Depression.

Martiny K.Dan Med J. 2017 Apr;64(4):B5338.PMID: 28385173 Review.


Cited by

T cells: an emerging cast of roles in bipolar disorder.

Chen Z, Huang Y, Wang B, Peng H, Wang X, Wu H, Chen W, Wang M.Transl Psychiatry. 2023 May 8;13(1):153. doi: 10.1038/s41398-023-02445-y.PMID: 37156764 Free PMC article. Review.

Neurodegeneration, Mitochondria, and Antibiotics.

Suárez-Rivero JM, López-Pérez J, Muela-Zarzuela I, Pastor-Maldonado C, Cilleros-Holgado P, Gómez-Fernández D, Álvarez-Córdoba M, Munuera-Cabeza M, Talaverón-Rey M, Povea-Cabello S, Suárez-Carrillo A, Piñero-Pérez R, Reche-López D, Romero-Domínguez JM, Sánchez-Alcázar JA.Metabolites. 2023 Mar 12;13(3):416. doi: 10.3390/metabo13030416.PMID: 36984858 Free PMC article. Review.

Anxiety-like behavior and microglial activation in the amygdala after acute neuroinflammation induced by microbial neuraminidase.

León-Rodríguez A, Fernández-Arjona MDM, Grondona JM, Pedraza C, López-Ávalos MD.Sci Rep. 2022 Jul 8;12(1):11581. doi: 10.1038/s41598-022-15617-5.PMID: 35803999 Free PMC article.

Roles of C-reactive protein polymorphisms and life event changes on cognitive function in bipolar patients receiving valproate.

Chen PS, Tang LY, Chang HH.Int J Immunopathol Pharmacol. 2022 Jan-Dec;36:3946320221084835. doi: 10.1177/03946320221084835.PMID: 35377256 Free PMC article.

Minocycline in Major Depressive Disorder: And overview with considerations on treatment-resistance and comparisons with other psychiatric disorders.

Nettis MA.Brain Behav Immun Health. 2021 Aug 24;17:100335. doi: 10.1016/j.bbih.2021.100335. eCollection 2021 Nov.PMID: 34568852 Free PMC article.


KMEL References